278.23
+4.13(+1.51%)
Currency In USD
| Previous Close | 274.1 |
| Open | 279.95 |
| Day High | 283.07 |
| Day Low | 275 |
| 52-Week High | 377.46 |
| 52-Week Low | 200.63 |
| Volume | 269,815 |
| Average Volume | 339,798 |
| Market Cap | 6.18B |
| PE | -15.6 |
| EPS | -17.84 |
| Moving Average 50 Days | 302.76 |
| Moving Average 200 Days | 293.83 |
| Change | 4.13 |
If you invested $1000 in Madrigal Pharmaceuticals, Inc. (MDGL) 10 years ago, it would be worth $3,298.52 as of June 07, 2025 at a share price of $278.23. Whereas If you bought $1000 worth of Madrigal Pharmaceuticals, Inc. (MDGL) shares 5 years ago, it would be worth $2,405.79 as of June 07, 2025 at a share price of $278.23.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference
GlobeNewswire Inc.
Jun 02, 2025 12:00 PM GMT
CONSHOHOCKEN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the 46th Annual Global Goldman Sachs Health Care Conference on Wednesday, June 11, 2025 at 10:40
Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis
GlobeNewswire Inc.
May 10, 2025 11:15 AM GMT
Late-breaking results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial presented at the EASL Congress65% of patients with clinically significant portal hypertension (CSPH) at baseline moved into lower risk
Madrigal to Present Late-Breaking Resmetirom Data in Patients with Compensated MASH Cirrhosis at the EASL Congress
GlobeNewswire Inc.
Apr 29, 2025 12:00 PM GMT
CONSHOHOCKEN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced s